Protagonist Therapeutics Cash from Financing (TTM) Analysis

Protagonist Therapeutics Inc (PTGX)

24.77 -0.93 (-3.62%) USD | NASDAQ | Apr 25, 12:26

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2015. Upgrade now.

Date	Value
December 31, 2023	170.48M
September 30, 2023	170.50M
June 30, 2023	135.87M
March 31, 2023	28.38M
December 31, 2022	18.84M
September 30, 2022	20.46M
June 30, 2022	21.16M
March 31, 2022	145.87M
December 31, 2021	129.92M
September 30, 2021	254.73M
June 30, 2021	261.02M
March 31, 2021	248.21M
December 31, 2020	247.63M
September 30, 2020	130.42M
June 30, 2020	147.99M
March 31, 2020	46.04M
December 31, 2019	46.04M

Date	Value
September 30, 2019	36.74M
June 30, 2019	34.53M
March 31, 2019	23.98M
December 31, 2018	24.12M
September 30, 2018	88.70M
June 30, 2018	65.70M
March 31, 2018	65.71M
December 31, 2017	65.55M
September 30, 2017	-0.36M
June 30, 2017	84.89M
March 31, 2017	84.05M
December 31, 2016	106.31M
September 30, 2016	107.16M
June 30, 2016	39.24M
March 31, 2016	40.05M
December 31, 2015	17.42M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

18.84M

Minimum

Dec 2022

261.02M

Maximum

Jun 2021

120.78M

Average

130.42M

Median

Sep 2020

Cash from Financing (TTM) Benchmarks